<DOC>
	<DOC>NCT01304303</DOC>
	<brief_summary>Phase I study of SPARC1023 alone and in combination with carboplatin</brief_summary>
	<brief_title>Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination</brief_title>
	<detailed_description>Pharmacokinetic profile and dose escalation study of SPARC1023 when administered as 30-min infusion.</detailed_description>
	<criteria>Age ≥18 years ECOG Performance Status ≤ 1. Estimated life expectancy of at least 12weeks; Measurable disease as per RECIST guideline (Version 1.1); Any malignancy within past 5years, except nonmelanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer Known hypersensitivity to the study drugs Treatment with any anticancer agents within 28 days of study entry Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>solid</keyword>
	<keyword>tumor</keyword>
	<keyword>taxane</keyword>
	<keyword>platinum</keyword>
</DOC>